Monday, April 22, 2019

Poseida Therapeutics Finds $142M

San Diego-based Poseida Therapeutics, a biopharmaceuticals startup developing non-viral gene engineering technology, has raised $142M in a Series C funding, the company said on Monday. According to the company, the funding was led by Novartis Pharma AG, which invested $75M in the round. Other investors in the round included Aisling Capital Management, P

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.

---